

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07J 41/00, 1/00, 31/00		A1	(11) International Publication Number: WO 98/31702
			(43) International Publication Date: 23 July 1998 (23.07.98)
(21) International Application Number: PCT/EP98/00377 (22) International Filing Date: 13 January 1998 (13.01.98) (30) Priority Data: 97200098.8 15 January 1997 (15.01.97) EP (34) Countries for which the regional or international application was filed: NL et al. (71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): GROEN, Marinus, Bernard [NL/NL]; Krijteweg 51, NL-5345 TT Oss (NL). GEBHARD, Ronald [NL/NL]; Kasteleinstraat 11, NL-5345 PV Oss (NL). (74) Agent: KRAAK, Hajo; P.O. Box 20, NL-5340 BH Oss (NL).			(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: **16-HYDROXY-11-(SUBSTITUTED PHENYL)-ESTRA-4,9-DIENE DERIVATIVES**

(57) Abstract

The present invention relates to 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives according to formula (I), wherein R₁ is C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkoxy, triflate, pyridyl or phenyl where the phenyl moiety is optionally substituted by one or more substituents selected from cyano, halogen and C₁₋₆alkyl; R₂ is hydrogen, C₁₋₆alkyl, 1-oxo-C₁₋₆alkyl or carboxy-1-oxo-C₁₋₆alkyl; R₃ is hydrogen, halogen or C₁₋₆alkyl optionally substituted by one or more substituents selected from C₁₋₆alkoxy and halogen; R₄ is hydrogen, C₁₋₆alkyl, 1-oxo-C₁₋₆alkyl or carboxy-1-oxo-C₁₋₆alkyl; and X is (H, OH), O or NOH; or a pharmaceutically acceptable salt or solvate thereof; to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment or prophylaxis of glucocorticoid dependent diseases or symptoms.



FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

16-HYDROXY-11-(SUBSTITUTED PHENYL)-ESTRA-4,9-DIENE DERIVATIVES

- The present invention relates to certain 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, in particular in the treatment or prophylaxis of glucocorticoid-dependent diseases.
- US patent No.5,089,635 discloses certain 13-alkyl-11 β -phenyl-gonanes having antigestagenic and antiglucocorticoid effects. European patent specification No.0,057,115 discloses 19-nor steroids and 19-nor-D-homo steroids having anti-glucocorticoid activity.
- A number of 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives have now been found which have a highly selective affinity to glucocorticoid receptors and have potent *in vivo* anti-glucocorticoid activity.

Accordingly, the present invention provides compounds of formula I



- wherein R₁ is C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkoxy, triflate, pyridyl or phenyl where the phenyl moiety is optionally substituted by one or more substituents selected from cyano, halogen and C₁₋₄alkyl;
- R₂ is hydrogen, C₁₋₆alkyl, 1-oxo-C₁₋₆alkyl or carboxy-1-oxo-C₁₋₆alkyl;
- R₃ is hydrogen, halogen or C₁₋₆alkyl optionally substituted by one or more substituents selected from C₁₋₆alkoxy and halogen;
- R₄ is hydrogen, C₁₋₆alkyl, 1-oxo-C₁₋₆alkyl or carboxy-1-oxo-C₁₋₆alkyl; and
- X is (H,OH), O or NOH;
- or a pharmaceutically acceptable salt or solvate thereof.

The present invention includes the 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives of formula I wherein:

1. R₁ is phenyl, triflate, or C₁₋₆alkyl, for example, t-butyl, isopropyl or methyl.
- 5 2. R₂ is hydrogen.
3. R₃ is hydrogen, halogen, for example, chloro, C₁₋₆alkyl, for example, methyl, ethyl, propyl or t-butyl optionally substituted by C₁₋₆alkoxy, such as methoxy.
4. R₄ is hydrogen or methyl.
- 10 5. X is O.
6. R₁, R₂, R₃, R₄ and X are as defined in points 1 to 5 *supra* or a pharmaceutically acceptable salt or solvate thereof.
7. R₁ is C₁₋₆alkyl, C₃₋₆cycloalkyl, triflate or phenyl; R₂ is hydrogen, C₁₋₆alkyl, 1-oxo-C₁₋₆alkyl or carboxy-1-oxo-C₁₋₆alkyl; R₃ is hydrogen, halogen or
15 C₁₋₆alkyl optionally substituted by one or more substituents selected from C₁₋₆alkoxy and halogen; R₄ is hydrogen, C₁₋₆alkyl, 1-oxo-C₁₋₆alkyl or carboxy-1-oxo-C₁₋₆alkyl; and X is (H,OH), O or NOH; or a pharmaceutically acceptable salt or solvate thereof.
- 20 Further examples of compounds of formula I above include examples 1 to 4.

As used herein the term alkyl means a straight or branched chain alkyl group. Such alkyl groups include methyl, ethyl, i-propyl, n-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl and neohexyl.

- 25 Reference to cycloalkyl includes cyclopropyl, cyclopentyl and cyclohexyl.

The term alkoxy has the meaning as understood by the person skilled in the art and includes straight and branched chains. Examples of alkoxy groups include methoxy and ethoxy. Preferred alkoxy groups include C₁₋₄alkoxy.

30

The term halogen includes chloro, bromo, fluoro and iodo.

Triflate means trifluoromethanesulphonate.

- 35 1-oxo-C₁₋₆alkyl or carboxy-1-oxo-C₁₋₆alkyl groups include 1-oxo-methyl, 1-oxo-ethyl, 1-oxo-propyl, 3-carboxy-1-oxopropyl, 3-carboxy-1-oxobutyl and 3-carboxy-1-oxopentyl.

Preferred examples of R_1 are phenyl and C_{1-6} alkyl, for example, t-butyl (1,1-dimethylethyl), isopropyl (1-methylethyl) or methyl, most preferably t-butyl and phenyl.

R_2 is preferably hydrogen.

5

Preferred examples of R_3 include C_{1-6} alkyl, most preferably methyl.

R_4 is preferably hydrogen or C_{1-6} alkyl, in particular methyl.

X is preferably O.

10

Preferred compounds of formula I include those wherein R_1 is phenyl or C_{1-6} alkyl, for example, t-butyl, isopropyl or methyl; R_2 is hydrogen; R_3 is C_{1-6} alkyl, most preferably methyl; R_4 is hydrogen or C_{1-6} alkyl, in particular methyl; and X is O; or a pharmaceutically acceptable salt or solvate thereof.

15

Particularly preferred 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives of formula I include:

20

(11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one

(11 β ,16 α ,17 β)-11-(4-isopropylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one;

25

(11 β ,16 α ,17 β)-11-(4-methylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one;

(11 β ,16 α ,17 β)-11-(1,1'-biphenyl-4-yl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one;

30

(11 β ,16 α ,17 β)-16,17-dihydroxy-11-[4-[(trifluoromethylsulfonyl)oxy]phenyl]-17-(1-propynyl)estra-4,9-dien-3-one;

or a pharmaceutically acceptable solvate thereof.

35

For therapeutic use, salts of the compounds of formula I are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable

compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

5 Salts according to the invention include ammonium salts, alkali metal salts such as those of sodium or potassium, alkali earth metals salts such as those of calcium and magnesium, salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine, and salts with amino acids, such as arginine and lysine.

Solvates according to the invention include hydrates.

10

In a further aspect of the invention there are provided the compounds of formula I and their pharmaceutically acceptable salts or solvates for use in therapy, more particularly in the treatment or prophylaxis of glucocorticoid dependent diseases or symptoms such as Cushing syndrome, diabetes, 15 glaucoma, sleep disturbances, depression, anxiety, atherosclerosis, hypertension, adiposity, osteoporosis, addiction and the treatment of the symptoms of withdrawal from substance abuse, for example, narcotics, cocaine and alcohol. The compounds also find use in the treatment of neurodegenerative diseases, such as, Alzheimers and psychotic disorders 20 such as schizophrenia, mania, hyperactivity, substance abuse, emesis and schizophreniaform disorders.

The compounds of formula I and their pharmaceutically acceptable salts and solvates and in particular the preferred compounds described *supra* are 25 useful for the treatment of depression.

The present invention further includes a method for the treatment of an animal, for example, a mammal including a human, suffering from or liable to suffer from a glucocorticoid dependent disease including any of the 30 aforementioned diseases or symptoms, which comprises administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof.

In yet a further aspect, the present invention provides the use of a compound 35 of formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment or prophylaxis of any of the aforementioned diseases or symptoms.

The amount of a compound of formula I or a pharmaceutically acceptable salt or solvate, also referred to herein as the active ingredient, which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated.

A suitable daily dose for any of the above mentioned disorders will be in the range of 0.001 to 50 mg per kilogram body weight of the recipient (e.g. a human) per day, preferably in the range of 0.01 to 20 mg per kilogram body weight per day and most preferably in the range 0.1 to 10 mg per kilogram body weight per day. The desired dose may be presented as one, two, three, four, five or more sub-doses administered at appropriate intervals throughout the day.

While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Accordingly, the present invention further provides a pharmaceutical formulation comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier thereof and optionally other therapeutic agents. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipients thereof.

Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal and intravitreal) administration. The formulations may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro *et al.*, Remington's Pharmaceutical Sciences (18th ed., Mack Publishing company, 1990, see especially Part 8: Pharmaceutical Preparations and their Manufacture). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. Such accessory ingredients include those conventional in the art, such as, fillers, binders, diluents, disintegrants, lubricants, colorants, flavoring agents and wetting agents.

Formulations suitable for oral administration may be presented as discrete units such as pills, tablets or capsules each containing a predetermined amount of active ingredient; as a powder or granules; as a solution or

suspension. The active ingredient may also be presented as a bolus or paste, or may be contained within liposomes.

5 Formulations for rectal administration may be presented as a suppository or enema.

For parenteral administration, suitable formulations include aqueous and non-aqueous sterile injection. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed vials and ampoules, and
10 may be stored in a freeze dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water prior to use.

Formulations suitable for administration by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurised
15 aerosols, nebulisers or insufflators.

The present invention further includes the following processes for the preparation of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof.


20

The compounds of formula I may be produced by various methods known in the art of organic chemistry in general. Starting materials are either known and readily available from chemical sources or may themselves be produced by conventional techniques.

25

In the following description the symbols R_1 , R_2 , R_3 , R_4 and X have the meanings ascribed to them in formula I unless otherwise stated.

According to a first general process (A), compounds of formula I may be prepared by dehydration and deprotection of a compound of formula II



30

wherein P is a protected keto group and R₅ is a group R₄ as defined in relation to formula I or a suitably protected R₄ group. Suitable protecting groups and methods to remove these groups are known in the art, for example from T.W. Green: Protective Groups in Organic Synthesis (Wiley, NY, 1981). Particularly suitable protecting groups for the protection of keto groups are acetals, for example, 1,2-ethylene ketal. Such groups may be removed, for example, by acid hydrolysis.

Dehydration may be carried out using methods known in the art. Typically, the reaction is carried out in the presence of a mineral acid, such as hydrochloric acid or sulphuric acid in a suitable solvent, for example, acetone in a temperature range of -20 to 25°C.

According to a second general process (B), compounds of formula I wherein X is (H,OH) may be prepared by treating a corresponding compound of formula I wherein X is O with a suitable reducing agent. For example, reduction with sodium borohydride in the presence of a solvent such as methanol, typically in a temperature range of 0 to 25°C.

According to a third general process (C), compounds of formula I wherein X is NOH may be prepared by condensation of a compound of formula I wherein X is O with a suitable oximating agent. For example, by treating the corresponding 3-keto compound with hydroxylamine in the presence of a suitable solvent such as pyridine.

Where necessary or desired, following the above process, any one or more of the following further steps in any order may be performed:

- (i) converting a compound of formula I into a pharmaceutically acceptable salt or solvate of a compound of formula I;
- (ii) converting a pharmaceutically acceptable salt or solvate of a compound of formula I into a compound of formula I; and
- (iii) converting a pharmaceutically acceptable salt or solvate of a compound of formula I into another pharmaceutically acceptable salt or solvate of a compound of formula I.

A suitable process for the preparation of derivatives of formula II starts with *estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal)* which may be prepared using methods described in EP 0683172 or according to the

method described herein below in example A. This compound is first converted into the 17-silylenoether using methods well known in the art, for example, by reaction with lithium diisopropylamide and trimethylsilylchloride, immediately followed by reaction with phenyl-trimethylammonium tribromide in pyridine. The resulting 16 α -bromo derivative is subsequently converted with sodium hydroxide in water and pyridine according to the procedure described in the J. Am. Chem. Soc. 102, 5402 (1980), into the corresponding 3-protected 16 α -hydroxysteroid. Alkynylation at C17 followed by (optional) protection of the 16-hydroxy function (e.g. as TBDMS-ether see T.W. Green: Protective Groups in Organic Synthesis, Wiley, NY, 1981) and epoxidation of the 5(10) double bond (e.g. with hydrogen peroxide, trifluoroacetophenone and pyridine in dichloromethane according to EP 0298020) provides the 16-hydroxy(protected)-3-ketoprotected 5 α ,10 α -epoxy-17 α -alkynyl-17 β -hydroxy-estr-9(11)-en-3-one. A copper catalyzed Grignard reaction with this epoxide eventually leads to compounds of formula II.

In the alternative, compounds of formula II may conveniently be prepared using estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal) as a starting material as herein before described. This compound may be converted into the corresponding 5 α 10 α -epoxide e.g. with hydrogen peroxide, trifluoroacetophenone and pyridine in dichloromethane according to the procedure described in EP 0298020. A copper catalyzed Grignard reaction provides the corresponding 3-protected-11-aryl-5-hydroxy-estr-9,10-en-17-one. Subsequent conversion into the 17-enol silyl derivative (by treatment with LDA and trimethylsilylchloride) followed by bromination with phenyl-trimethylammonium tribromide in pyridine provides the corresponding 16-bromide. The desired 16 α -hydroxy function is introduced by nucleophilic substitution [sodium hydroxide, pyridine/water, according to the procedure described in J. Am. Chem. Soc. 102, 5402 (1980)]. Propynylation (propyne, n-BuLi) finally leads to the desired compound II.

Compounds of formula I may be converted into a pharmaceutically acceptable 1-oxo-C₁₋₄alkyl or carboxy-1-oxo-C₁₋₄alkyl by reaction with an appropriate esterifying agent, for example, by treatment with an appropriately activated carboxylic acid, like for example an acid chloride, or an activated dicarboxylic acid, like for example a cyclic anhydride, using methods well known in the art.

The compounds of formula I, may be converted into pharmaceutically acceptable salts thereof in a conventional manner, for example by treatment with the appropriate acid.

- 5 The present invention further includes all novel intermediates defined herein and in particular compounds of formula II.

Particularly preferred intermediates include:

- 10 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-17 α -propynyl-estr-9-en-3-one
3-(cyclic 1,2-ethanediyl acetal);

5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-17 α -pentynyl-estr-9-en-3-one
3-(cyclic 1,2-ethanediyl acetal);

- 15 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-17 α -hexynyl-estr-9-en-3-one
3-(cyclic 1,2-ethanediyl acetal);

- 20 5 α ,17 β -dihydroxy-11 β -[4-t-butylphenyl]-16 α -methoxy-17 α -propynyl-estr-9-en-
3-(cyclic 1,2-ethanediyl acetal);

21-chloro-11-(4-t-butylphenyl)-5 α ,16 α ,17 β -trihydroxy-19-norpregn-9-en-20-
yn-3-one 3-(cyclic 1,2-ethanediyl acetal);

- 25 or a pharmaceutically acceptable salt or solvate thereof.

The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way.

30 **Example A.**

Estra-5(10),9(11)-diene)-3,17-dione 3,3-ethyleneketal

- 35 A mixture of 500 ml of cyclohexane, 183 ml of triethyl orthoformate, 92 ml of ethylene glycol and 0.9 g of p-toluenesulphonic acid was stirred for 30 minutes at room temperature and thereafter heated to reflux. The formed ethanol was together with cyclohexane distilled off but the volume was kept constant by addition of cyclohexane. After 4.5 hours the residue of cyclohexane was distilled off and 1 eq. of the residue was added as a water scavenger under an atmosphere of nitrogen to 1 g of estra-4,9-diene-3,17-

dione, 0.1 eq. of hydrogen chloride in dioxane and 1.5 eq. of ethylene glycol in 15 ml of dimethoxyethane at -10°C. After 75 min. the reaction mixture was poured into a saturated aqueous solution of sodium hydrogen carbonate. The crystal mass was filtered off, washed with water and dried *in vacuo*, after
5 which 1.1 g of estra-5(10),9(11)-diene-3,17 dione 3,3- ethyleneketal was obtained. After crystallisation from ethanol 1 g of product was obtained having a purity of better than 97%.

Example 1.

10

(11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one

a) 16-bromo-estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediylacetal)
15 A solution of 192 mmol LDA (prepared by adding 120 ml of a 1.6 M n-BuLi solution to a solution of 34 ml diisopropylamine in 340 ml of dry THF) was added dropwise to a cold (-30 °C) solution of 50 g (159 mmol) of estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal) in 480 ml dry THF. Stirring was continued for 15 min. at -30 °C. Then, 60 ml (473 mmol) of
20 trimethylsilylchloride was added dropwise and the solution was allowed to warm to 0 °C over ca. 1 hour. Phenyl-trimethylammonium tribromide (60 g, 160 mmol), dissolved in 60 ml pyridine, was slowly added to this solution of the enol ether and after one hour the reaction mixture was warmed to room temperature. TLC indicated complete disappearance of the starting material
25 and the formation of a more lipophilic product (toluene/ethyl acetate; 85/15). Work-up was accomplished by pouring the reaction mixture into a cold ammonium chloride solution followed by extraction with dichloromethane. Drying with magnesium sulfate, filtration and evaporation of the solvents gave a semi-solid mass. Crystallisation from ethanol gave 41.8 g of the desired
30 bromide (predominantly alpha) as off-white crystals (m.p. 166.8-167.8 °C).

b) 16 α -hydroxy-estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal)

40 g (101 mmol) of the product obtained under a) was dissolved in 840 ml dry
35 pyridine. Under stirring, 240 ml water was added, followed by 120 ml of a 1N NaOH solution. The temperature was kept below 25 °C. After stirring for 30 min. at room temperature, TLC indicated complete conversion. The mixture was poured into a saturated ammonium chloride solution. Extraction with dichloromethane, drying with magnesium sulfate and evaporation of the

solvents provided the crude hydroxy compound as an oil. Column chromatography (silica gel, heptane/ethyl acetate 8/2) provided 18.8 g. of the pure 16 α -hydroxy-estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal) as a foam. An analytical sample, crystallized from diethyl ether, afforded white crystals; m.p. 188.4 - 190.6 °C.

c) *16 α ,17 β -dihydroxy-17 α -propynyl-estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal)*

Into a three-necked flask, equipped with a gas-inlet tube and a dropping funnel containing 130 ml dry THF at -70 °C, was added 106 ml of a 1.6 N n-BuLi solution in hexane. The solution turned yellow. Propyne gas was bubbled through this solution until the yellow colour disappeared. A white suspension had formed and stirring was continued for 15 min at -70 °C. Then, a solution of 18 g (54.3 mmol) of the previously obtained product, dissolved in 150 ml dry THF, was added dropwise to the cold solution of the propyne anion. After addition, the solution was allowed to warm slowly to -20 °C. After stirring for 2 hrs at that temperature, TLC indicated complete conversion of the starting material. Work-up was accomplished by pouring the mixture into a saturated ammonium chloride solution, followed by extraction with dichloromethane. Drying with magnesium sulfate and evaporation of the solvents provided 19.8 g of the crude material. Purification using a short column (silica gel, heptane/ethyl acetate 1/1) provided 15.9 g of the desired pure compound. Crystallization of an analytical sample from diethyl ether afforded white crystals, m.p. 71 °C.

25

d) *16-TBDMS ether of 16 α ,17 β -dihydroxy-17 α -propynyl-estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal)*

15.9 g (42.9 mmol) of the product obtained under c) was dissolved in 60 ml dry DMF. To this solution, 15 g imidazole was added followed by 15 g (120 mmol) of t-butyldimethylsilylchloride. After stirring for 3 hrs at 40 °C, TLC analysis indicated a quantitative conversion of the starting compound into one lipophilic product. The mixture was quenched with ammonium chloride solution, followed by extraction with dichloromethane. Drying with magnesium sulfate, followed by evaporation of the solvents afforded 35 g of the crude silyl compound which was used as such in the next step.

35

e) 16-TBDMS-ether of 5 α ,10 α -epoxy-17 α -propynyl-17 β -hydroxy-estr-9(11)-en-3-one-3-(cyclic-1,2-ethanediyl acetal)

35 g of the crude product obtained under d) (maximum amount of pure compound 20.8 g, 42.9 mmol) was dissolved in 300 ml of dichloromethane; subsequently 2 ml of pyridine, 5.3 ml of trifluoroacetophenone and 70 ml of 30% hydrogen peroxide were added and the resulting two-phase system was vigorously stirred at ambient temperature for 48 hours. The mixture was poured into water and the organic layer was separated and washed twice with saturated sodium thiosulfate solution. Drying with anhydrous magnesium sulfate, filtering and evaporation provided a semi-solid residue. Purification with column chromatography provided 16.4 g of the desired α -epoxide as amorphous material.

*f) 16-TBDMS-ether of 5 α ,16 α ,17 β -trihydroxy-11 β -[4-*t*-butylphenyl]-17 α -propynyl-estr-9-en-3-one 3-(cyclic 1,2-ethanediyl acetal)*

330 mg of CuCl were added at 0-5° C to a solution of 4-*t*-butylphenylmagnesium bromide (prepared from 0.83 g (35 mmol) Mg and 6.0 ml (34.5 mmol) 4-bromo-*t*-butylbenzene in 50 ml dry THF). After stirring for 30 min. at 0-5 °C, 2.5 g (5 mmol) of the previously obtained epoxide, dissolved in 30 ml dry THF were added dropwise, while keeping the temperature below 10° C. Stirring was continued for one hour at ambient temperature. Work-up was accomplished by pouring the mixture into a saturated ammonium chloride solution and extraction with ethyl acetate (2x). The combined organic layers were washed with brine, dried with anhydrous magnesium sulfate, filtered and concentrated. Column chromatography (silica gel, heptane/ethyl acetate 7/3) provided 2.7 g of the pure 11-substituted compound as white amorphous material.

*g) (11 β ,16 α ,17 β)-11-(4-*t*-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one*

2.7 gr (4.26 mmol) of the compound obtained under f) was dissolved in 50 ml acetone. At room temperature 3 ml 6N H₂SO₄ was added and the mixture was stirred for two hours. Then, the cold solution was poured into saturated sodium bicarbonate solution and the mixture was extracted with ethyl acetate (2x). The combined organic layers were washed with brine, dried with anhydrous magnesium sulfate, filtered and concentrated. Chromatography (dichloromethane/acetone 8/2) provided 1.6 g of the desired (11 β ,16 α ,17 β)-11-(4-*t*-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one as

a white solid. Crystallisation from diethyl ether afforded 1.2 g white crystals, m.p. 251.6-253.8 °C.

Alternative procedure

- 5 a) *5 α ,10 α -epoxy-estra-9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal)*
150 g of *estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1,2-ethanediyl acetal)*
478 mmol) was dissolved in 2.2 l of dichloromethane; subsequently 14.4 ml of
pyridine, 48 ml of trifluoroacetophenone and 666 ml of 30% hydrogen
10 peroxide were added and the resulting two-phase system was vigorously
stirred at ambient temperature for 48 hours. The mixture was poured into
water and the organic layer was separated and washed twice with saturated
sodium thiosulfate solution. Drying with anhydrous magnesium sulfate,
filtering and evaporation provided a semi-solid residue. Crystallisation from
ether/heptane afforded 80 g of the desired α -epoxide as white crystalline
15 material (m.p. 153 °C).

*b) 5 α -hydroxy-11-(4-*t*-butylphenyl)-estr-9-en-3,17-dione-3-(cyclic 1,2-ethanediyl-acetal)*

- 900 mg of CuCl were added at 0-5° C to a solution of 20 g (60 mmol) of the
20 previously obtained epoxide dissolved in 30 ml dry THF. The mixture was
stirred for 20 min. and slowly a solution of 4-*t*-butylphenylmagnesium bromide
(prepared from 5 g (200 mmol) Mg and 32.8 ml (200 mmol) 4-bromo-*t*-
butylbenzene in 150 ml dry THF), were added dropwise, while keeping the
temperature below 10° C. Stirring was continued for one hour at ambient
25 temperature. Work-up was accomplished by pouring the mixture into
saturated ammonium chloride solution and extracting with ethyl acetate (2x).
The combined organic layers were washed with brine, dried with anhydrous
magnesium sulfate, filtered and concentrated. Column chromatography (silica
gel, heptane/ethyl acetate 7/3) provided 28 g of the desired 5 α -hydroxy-11 β -
30 [4-*t*-butylphenyl]estr-9-ene-3-one 3-(cyclic 1,2-ethanediyl acetal).

*c) 16 α -bromo-5 α -hydroxy-11 β -[4-*t*-butylphenyl]estra-9-ene-3-one-3-(cyclic 1,2-ethanediyl acetal)*

- A solution of 181 mmol LDA (prepared by adding 113 ml of a 1.6 M *n*-BuLi
35 solution to a solution of 25.6 ml diisopropylamine in 400 ml dry THF) was
added dropwise to a cold solution (-60 °C) of 28 g (60 mmol) 5 α -hydroxy-11 β -
[4-*t*-butylphenyl]estr-9-en-3-one 3-(cyclic 1,2-ethanediyl acetal) in 700 ml dry
THF. Stirring was continued for 30 min at -50°C. Then 38.3 ml of

trimethylsilylchloride was added dropwise and the solution was stirred at -45 °C for 1 hour. After cooling the reaction mixture to -60 °C, 27.7 g (72.4 mmol) phenyltrimethylammonium tribromide, dissolved in 100 ml pyridine, was added dropwise. After 2 hours stirring at -60 °C TLC indicated complete disappearance of the starting material and the formation of a more lipophilic product (heptane/ethyl acetate; 6/4). Work-up was accomplished by pouring the reaction mixture into ammonium chloride solution, followed by extraction with ethyl acetate. Drying over magnesium sulfate, filtration and evaporation of the solvents gave a semi-solid mass. Crystallisation from heptane, followed by a crystallisation from ethanol gave 20 g of the desired bromide as white crystals (m.p. 164-165 °C).

d) *5 α ,16 α -dihydroxy-11 β -[4-*t*-butylphenyl]estr-9-en-3,17-dione-3-(cyclic 1,2-ethanediyl acetal)*
12.5 g (23.0 mmol) of the product obtained under a) was suspended in 400 ml 75% pyridine in water. 27.5 ml 1 M NaOH was added. After stirring for 30 min at room temperature the starting compound was dissolved and TLC indicated complete conversion.
The reaction mixture was poured into ammonium chloride solution and extracted with ethyl acetate. Drying with magnesium sulfate, evaporation of the solvents and co-evaporation with toluene provided the crude hydroxy compound. Crystallisation from diisopropyl ether gave 9.0 g of the desired compound (m.p. 180-182 °C).

e) *5 α ,16 α ,17 α -trihydroxy-11 β -[4-*t*-butylphenyl]-17-(1-propynyl)estr-9-en-3-one-3-(cyclic 1,2-ethanediyl acetal)*
Into a three-necked flask, equipped with a gas-inlet tube and a dropping funnel containing 130 ml dry THF at -70 °C, was added 95 ml of a 1.6 N *n*-BuLi solution in hexane. The solution turned yellow. Propyne gas was bubbled through this solution until the yellow colour disappeared. A white suspension had formed and stirring was continued for 15 min at -70 °C. Then, a solution of 18 g (38 mmol) of the previously obtained product, dissolved in 150 ml dry THF, was added dropwise to the cold solution of the propyne anion. After the addition, the solution was allowed to warm slowly to -20 °C. After stirring for 2 hrs at that temperature, TLC indicated complete conversion of the starting material. Work-up was accomplished by pouring the mixture into saturated ammonium chloride solution, followed by extraction with dichloromethane. Drying over magnesium sulfate and evaporation of the solvents provided 19.8 g of the crude material. Purification using a short

column (silica gel, heptane/ethyl acetate 1/1) provided 18.5 g of the desired pure compound as a white foam.

f) (11 β ,16 α ,17 β)-11-(4-*t*-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)-estra-4,9-dien-3-one

2.7 g (4.26 mmol) of the compound obtained under e) was dissolved in 50 ml acetone. At room temperature 3 ml 6N H₂SO₄ was added and the mixture was stirred for two hours. Then, the cold solution was poured into saturated sodium bicarbonate solution and the mixture was extracted with ethyl acetate (2x). The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. Chromatography (dichloromethane/acetone 8/2) provided 1.6 g of the desired (11 β ,16 α ,17 β)-11-(4-*t*-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one as a white solid. Crystallisation from diethyl ether afforded 1.2 g white crystals, m.p. 251.6-253.8 °C.

By substitution of the 4-bromo-*t*-butylbenzene by 4-bromo-isopropylbenzene, 4-bromo-toluene and 4-bromo-biphenyl, the following products have been obtained:

1A. (11 β ,16 α ,17 β)-11-(4-isopropylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one; m.p. 153.4-154.9 °C.

1B. (11 β ,16 α ,17 β)-11-(4-methylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one; m.p. 212.2-213.8 °C.

1C. (11 β ,16 α ,17 β)-11-(1,1'-biphenyl-4-yl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one; m.p. 254.8-256.2 °C.

1D. 3E- and 3Z-(11 β ,16 α ,17 β)-11-(4-*t*-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)-estra-4,9-dien-3-one oxime:

Preparation: 200 mg (0.44 mmol) of (11 β ,16 α ,17 β)-11-(4-*t*-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one (obtained as described in 1f) was dissolved in 1 ml pyridine. 70 mg (0.88 mmol) of hydroxylamine hydrochloride was added and the mixture was stirred at reflux temperature for 40 minutes. The mixture was poured into water, neutralised with dilute hydrochloric acid and extracted with ethyl acetate. The organic layer was

washed with brine, dried over magnesium sulfate, filtered and evaporated to dryness. The crude oxime was subjected to a HPLC separation (acetonitrile/water 40/60 → 60/40) resulting in 39 mg 3Z-(11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)-estra-4,9-dien-3-one oxime ([α]_D²⁰ = +30° (c=0.2, dioxane)) and 75 mg of 3E-(11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)-estra-4,9-dien-3-one oxime ([α]_D²⁰ = +60° (c=0.6, dioxane)).

10 **Example 2.**

(11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-19,21,27-trinorcholesta-4,9-dien-20(22)-yn-3-one

15 a) 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-17 α -hexynyl-estr-9-en-3-one 3-(cyclic 1,2-ethanediyl acetal)

1-Hexyne (2.88 g, 4 ml, 35 mmol) was dissolved in 75 ml dry THF; after cooling the solution to -20 °C, 20 ml of a 1.6 M nBuLi solution was added dropwise and the mixture was stirred at -20 °C for 15 min. Then, a solution of
20 2.4 g 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-estr-9-en-3,17-dione 3-(cyclic 1,2-ethanediyl acetal) in 50 ml THF was added dropwise and stirring was continued for 1 hr at -20 °C.

Work-up was accomplished by pouring the mixture into saturated ammonium chloride solution, followed by extraction with ethyl acetate (2x), washing the
25 combined organic layers with brine, drying with magnesium sulfate and evaporation of the solvents. This afforded the crude product as an oil. Trituration with diisopropyl ether afforded 800 mg of pure 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-17 α -hexynyl-estr-9-en-3-one 3-(cyclic 1,2-ethanediyl acetal) as white crystals; m.p. 182-183 °C.

30

b) (11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-19,21,27-trinorcholesta-4,9-dien-20(22)-yn-3-one

The 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-17 α -hexynyl-estr-9-en-3-one 3-(cyclic 1,2-ethanediyl acetal) obtained in the previous experiment was
35 dissolved in 50 ml acetone; 1 ml 6N H₂SO₄ was added and stirring was continued for 30 min. TLC (heptane/ethyl acetate 1/1) showed complete conversion of the starting material into two lipophilic products. Work-up was accomplished by addition of saturated NaHCO₃ solution, followed by

extraction with ethyl acetate (2x), washing the combined organic layers with brine and drying over magnesium sulfate. Evaporation of the solvents gave the crude compound as an oil. Column chromatography (heptane-ethyl acetate 8/2 → 6/4) provided 500 mg of the desired (11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-19,21,27-trinorcholesta-4,9-dien-20(22)-yn-3-one as amorphous white material; $[\alpha]_D^{20} = 34.2$ (c = 0.5, dioxane).

The following products were prepared according to examples 2a and 2b by using 1-pentyne, 3-methoxypropyne and acetylene, respectively:

10

2A. (11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(1-pentynyl)estra-4,9-dien-3-one; $[\alpha]_D^{20} = 37.8$ (c = 1, dioxane).

15

2B. (11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(3-methoxy-1-propynyl)estra-4,9-dien-3-one; m.p. 171.0 - 171.6 °C.

2C. (11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-19-norpregna-4,9-dien-20-yn-3-one; $[\alpha]_D^{20} = 46.9$ (c = 1, dioxane).

20

2D. (11 β ,16 α ,17 β)-16,17-dihydroxy-11-[4-(trifluoromethylsulphonyl)oxy]phenyl]-17-(1-propynyl)estra-4,9-dien-3-one; $[\alpha]_D^{20} = 8.9$ (c=1 dioxane).

Example 3

25

(11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-17-hydroxy-16-methoxy-17-(1-propynyl)estra-4,9-dien-3-one

30

a) 5 α -hydroxy,11 β -[4-t-butylphenyl]-16 α -methoxy-estr-9-en-3,17-dione 3-(cyclic 1,2-ethanediyl acetal)

35

2.0 g (4.16 mmol) 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-estr-9-ene-3,17-dione 3-(cyclic 1,2-ethanediyl acetal) was dissolved in 150 ml dry dichloromethane. To this solution 4.5 g 2,6-di-t-butyl-4-methylpyridine (15.75 mmol) and 1.3 g trimethyloxonium-tetrafluoroborate (8.3 mmol) were added and the solution was stirred at room temperature. After three hours, TLC analysis (heptane/ethyl acetate/ethanol 10/10/1) indicated complete conversion of the starting compound. Work-up was accomplished by addition of saturated sodium bicarbonate solution, followed by extraction with

dichloromethane. Evaporation of the solvent gave 2.6 g crude product, pure enough to be used in the next step.

5 **b) *5 α ,17 β -dihydroxy-11 β -[4-*t*-butylphenyl]-16 α -methoxy-17 α -propynyl-estr-9-en-3-one-3-(cyclic 1,2-ethanediyl acetal)***

The material obtained in the previous reaction was dissolved in 10 ml dry THF and added dropwise to a solution of propynyl lithium (prepared by adding propyne gas to a solution of 20 ml 1.3 M *n*-BuLi until the yellow colour disappeared and changed into a white suspension) at -60 °C. The solution
10 was allowed to warm to -20 °C and stirring was continued for 1 hr. Work-up was accomplished by pouring the mixture into a saturated ammonium chloride solution, followed by extraction with dichloromethane. Drying with magnesium sulfate and evaporation of the solvents gave the crude product which was purified with column chromatography (heptane/ethyl acetate 1/1).
15 Yield: 1.15 g of the desired *5 α ,17 β -dihydroxy-11 β -[4-*t*-butylphenyl]-16 α -methoxy-17 α -propynyl-estr-9-en-3-one-3-(cyclic 1,2-ethanediyl acetal)* as amorphous white material.

20 **c) *(11 β ,16 α ,17 β)-11-(4-*t*-butylphenyl)-17-hydroxy-16-methoxy-17-(1-propynyl)-estra-4,9-dien-3-one***

The material (1.15 g) obtained in the previous reaction was dissolved in 20 ml acetone; 2 ml 2 N HCl were added and the mixture was stirred for 2 hrs at ambient temperature. Neutralisation with sodium bicarbonate solution and
25 extraction with ethyl acetate provided, after washing with brine and drying over magnesium sulfate, the crude product. Column chromatography (heptane/ethyl acetate 1/1) provided 700 mg of the pure title compound as amorphous material; $[\alpha]_D^{20} = 50.1$ (*c* = 0.5, dioxane).

Example 4

(11 β ,16 α ,17 β)-21-chloro-11-(4-t-butylphenyl)-16,17-dihydroxy-19-norpregna-4,9-dien-20-yn-3-one

a) 21-chloro-11-(4-t-butylphenyl)-5 α ,16 α ,17 β -trihydroxy-19-norpreg-9-en-20-yn-3-one 3-(cyclic 1,2-ethanediyl acetal)

10 Methylolithium (11 ml 2.2 M solution in diethyl ether) was added dropwise at 0 °C to a solution of 1.2 g trans-1,2-dichloroethene (12 mmol) in 5 ml dry diethyl ether. Stirring was continued at room temperature for 1.5 hrs. Then, a solution of 1.4 g (3 mmol) 5 α ,16 α ,17 β -trihydroxy-11 β -[4-t-butylphenyl]-estr-9-ene-3,17-dione 3-(cyclic 1,2-ethanediyl acetal) dissolved in 20 ml dry toluene
15 was added dropwise and stirring was continued for 1 hr at ambient temperature. Work-up was accomplished by addition of saturated ammonium chloride solution, followed by extraction with ethyl acetate. Washing the organic layers with brine, drying over magnesium sulfate and evaporation of the solvents provided 2 g of the crude material. Column chromatography
20 (heptane/ethyl acetate 1/1) provided 1.2 g of the desired 21-chloro-11-(4-t-butylphenyl)-5 α ,16 α ,17 β -trihydroxy-19-norpregn-9-en-20-yn-3-one 3-(cyclic 1,2-ethanediyl acetal) as white amorphous material pure enough to be used in the next step.

25 ***b) (11 β ,16 α ,17 β)-21-chloro-11-(4-t-butylphenyl)-16,17-dihydroxy-19-norpregna-4,9-dien-20-yn-3-one***

According to the procedure described in example 3c, the material obtained in the previous reaction step gave after column chromatography 460 mg of the
30 desired (11 β ,16 α ,17 β)-21-chloro-11-(4-t-butylphenyl)-16,17-dihydroxy-19-norpregna-4,9-dien-20-yn-3-one, which could be crystallized from diethyl ether, m.p. 202.2-202.7 °C (decomposes).

Example 5**Glucocorticoid Receptors (GR) and Progesterone Receptors (PR) Binding Affinities**

5

In the following Table the receptor affinity of the compounds of the invention for glucocorticoid receptors (GR) related to progesterone receptors (PR) is presented.


- 10 The glucocorticoid affinity of the compounds was measured for glucocorticoid receptors present in intact human multiple myeloma cells and compared with the affinity of dexamethasone (according to the procedure described by H.J. Kloosterboer et al., J. Steroid Biochem., Vol. 31, 567-571 (1988)).

- 15 The progesterone affinity of the compounds was measured for cytoplasmic progesterone receptors present in human breast tumor cells and compared with the affinity of (16 α)-16-ethyl-21-hydroxy-19-norpregn-4-en-3,20-dione (according to the procedure described by E.W. Bergink et al., J. Steroid Biochem., Vol. 19, 1563-1570 (1983)).

20 **Results**

Example	GRcyt(%)	PRcyt(%)
1	372	3.6
1A	317	2.9
2D	136	1.1
RU	193	36
(38)486		
(Schering)	39	0.3
11 p-acetyl		

- 25 Compounds of the present invention were compared with 11 β -(4-acetylphenyl)-16 α ,17 β -dihydroxy-17 α -(1-propynyl)estra-4,9-dien-3-one (the "11 p-acetyl" compound) disclosed in US patent No.5,089,635 and RU (38)486. The compounds according to the present invention showed high GRcyt while the undesired PRcyt activity was low.

CLAIMS**1. A compound of formula I**

wherein R_1 is C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkoxy, triflate, pyridyl or phenyl where the phenyl moiety is optionally substituted by one or more substituents selected from cyano, halogen and C_{1-4} alkyl;

R_2 is hydrogen, C_{1-6} alkyl, 1-oxo- C_{1-6} alkyl or carboxy-1-oxo- C_{1-6} alkyl;

R_3 is hydrogen, halogen or C_{1-6} alkyl optionally substituted by one or more substituents selected from C_{1-6} alkoxy and halogen;

R_4 is hydrogen, C_{1-6} alkyl, 1-oxo- C_{1-6} alkyl or carboxy-1-oxo- C_{1-6} alkyl; and

X is (H,OH), O or NOH;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 wherein R_1 is phenyl, triflate or C_{1-6} alkyl; R_2 is hydrogen; R_3 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by C_{1-6} alkoxy; R_4 is hydrogen or methyl; X is O; or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 or 2 wherein R_1 is phenyl or C_{1-6} alkyl; R_2 is hydrogen; R_3 is C_{1-6} alkyl; R_4 is hydrogen or C_{1-6} alkyl; and X is O; or a pharmaceutically acceptable salt or solvate thereof.

4. A compound according to any of claims 1 to 3 wherein R_1 is phenyl, t-butyl, isopropyl or methyl; R_2 is hydrogen; R_3 is methyl; R_4 is hydrogen or methyl; and X is O; or a pharmaceutically acceptable salt or solvate thereof.

5. A compound according to any of claims 1 to 4 selected from:

- 5 (11 β ,16 α ,17 β)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)
estra-4,9-dien-3-one;
- (11 β ,16 α ,17 β)-11-(4-isopropylphenyl)-16,17-dihydroxy-17-(1-propynyl)
estra-4,9-dien-3-one;
- 10 (11 β ,16 α ,17 β)-11-(4-methylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-
4,9-dien-3-one;
- (11 β ,16 α ,17 β)-11-(1,1'-biphenyl-4-yl)-16,17-dihydroxy-17-(1-propynyl)
estra-4,9-dien-3-one;
- 15 (11 β ,16 α ,17 β)-16,17-dihydroxy-11-[4-(trifluoromethylsulfonyl)oxy]phenyl]-
17-(1-propynyl)estra-4,9-dien-3-one;


or a pharmaceutically acceptable salt or solvate thereof.

20

6. A compound of formula I or a pharmaceutically acceptable salt or solvate thereof, as defined according to any of claims 1 to 5 for use in therapy.
- 25 7. Use of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, as defined according to any of claims 1 to 5, in the manufacture of a medicament for the treatment or prophylaxis of glucocorticoid dependent diseases or symptoms.
- 30 8. A pharmaceutical formulation comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, as defined according to any of claims 1 to 5, together with a pharmaceutically acceptable carrier.

9. A process for the preparation of a compound of formula I as defined in any of claims 1 to 5, comprising dehydration and deprotection of a compound of formula II

5




wherein P is a protected keto group and R₅ is a group R₄ as defined in claim 1 or a suitably protected R₄ group;

- 10 optionally followed by treatment with a suitable reducing agent or with a suitable oximating agent; and optional conversion into a pharmaceutically acceptable salt or solvate.

10. A compound of formula II

15



wherein R₁, R₂ and R₃ are as defined in claim 1, R₅ is a group R₄ as defined in claim 1 or a suitably protected R₄ group and P is a protected keto group.

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/00377

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07J41/00 C07J1/00 C07J31/00

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07J A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 190 759 A (SCHERING AG) 13 August 1986 see example 21 ---	1-10
Y	DE 33 07 143 A (ROUSSEL UCLAF) 8 September 1983 see examples 8,14,28,39 -----	1-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 May 1998

Date of mailing of the international search report

08/06/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/00377

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0190759	A	13-08-1986	DE 3504421 A	07-08-1986
			DE 3527517 A	29-01-1987
			AU 580843 B	02-02-1989
			AU 5291386 A	14-08-1986
			CA 1310630 A	24-11-1992
			CN 1033753 B	08-01-1997
			DK 56086 A,B,	08-08-1986
			FI 860559 A,B	08-08-1986
			IE 58149 B	14-07-1993
			JP 1749287 C	08-04-1993
			JP 4037080 B	18-06-1992
			JP 61183296 A	15-08-1986
			PT 81969 B	03-03-1988
			US 5089635 A	18-02-1992
DE 3307143	A	08-09-1983	FR 2522328 A	02-09-1983
			AT 396109 B	25-06-1993
			AU 562739 B	18-06-1987
			AU 1191383 A	08-09-1983
			BE 896042 A	29-08-1983
			CA 1206471 A	24-06-1986
			CA 1215353 C	16-12-1986
			CH 657368 A	29-08-1986
			DK 89783 A	02-09-1983
			EG 15881 A	30-06-1991
			FI 830652 A,B,	02-09-1983
			WO 8303099 A	15-09-1983
			FR 2639045 A	18-05-1990
			GB 2118186 A,B	26-10-1983
			JP 1830326 C	15-03-1994
			JP 5004397 B	19-01-1993
			JP 58201800 A	24-11-1983
			JP 1754269 C	23-04-1993
			JP 2275895 A	09-11-1990
			JP 4043920 B	20-07-1992
			LU 84667 A	08-09-1983
			NL 8300738 A	03-10-1983
			OA 7567 A	31-03-1985
			PT 76307 B	27-01-1986
			SE 8300308 A	02-08-1983

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/00377

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 3307143 A		SU 1340593 A	23-09-1987
		US 5064822 A	12-11-1991
		US 4477445 A	16-10-1984
		US 4540686 A	10-09-1985
		US 5182381 A	26-01-1993
<hr/>			